Company: APM
Filing Date: 2025-11-17
Form Type: F-1
Source: 0001213900-25-111548
Chunk: 41

Company: Aptorum Group Ltd
Filing Date: 2025-11-17
Form: F-1
Chunk 41
---
ks related to Aptorum and DiamiR shareholders not realizing a benefit from the Merger commensurate with the ownership dilution they will experience in connection with the Merger. |

| ● | Risks related to Aptorum and DiamiR being prohibited from seeking out alternative business combinations before the Merger is complete, especially if it is never consummated. |

| ● | Risks related to management of the Combined Company. |

| ● | Because DiamiR has yet to generate revenue from product sales on which to evaluate its potential for future success and to determine if DiamiR will be able to execute its business plan, it is difficult to evaluate DiamiR’s prospects and the likelihood of success or failure of its business. |

Risks Related to Doing Business in Hong Kong

| ● | Risks relating to legal and regulatory risks associated with our operations in Hong Kong.                                                                                                                                                                                                                                                                                                                                |
| ● | If we become directly subject to the recent scrutiny, criticism and negative publicity involving U.S.-listed Chinese companies, we may have to expend significant resources to investigate and resolve the matter which could harm our business operations, stock price and reputation and could result in a loss of your investment in our stock, especially if such matter cannot be addressed and resolved favorably. |
| ● | The recent joint statement by the SEC, proposed rule changes submitted by Nasdaq, and an act passed by the U.S. Senate and the U.S. House of Representatives, all call for additional and more stringent criteria to be applied to emerging market companies. These developments could add uncertainties to our offering, business operations, share price and reputation.                                               |
| ● | Our business, financial condition and results of operations, and/or the value of our Class A Ordinary Shares or our ability to offer or continue to offer securities to investors may be materially and adversely affected to the extent the laws and regulations of the PRC become applicable to a company such as us.                                                                                                  |

17

| ● | The uncertainties with respect to the Chinese legal system, including uncertainties regarding the enforcement of laws, and sudden or unexpected changes in laws and regulations in China with little advance notice could adversely affect us and limit the legal protections available to you and us. |

Risks Related to the Preclinical and Clinical Development of Our Drug Candidates

| ● | Risks relating to not generate sufficient revenue |

| ● | Risks relating to uncertainty in preclinical development process |

| ● | Risks relating to fail to identify additional drug candidates |

| ● | Risks relating to